Related references
Note: Only part of the references are listed.α-Synuclein oligomers and clinical implications for Parkinson disease
Lorraine V. Kalia et al.
ANNALS OF NEUROLOGY (2013)
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease
A. H. V. Schapira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2013)
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
Anthony H. V. Schapira et al.
LANCET NEUROLOGY (2013)
Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain
J. W. Steele et al.
MOLECULAR PSYCHIATRY (2013)
Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2013)
Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity
Mickael Decressac et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Actively Transported Levodopa Prodrug XP21279: A Study in Patients With Parkinson Disease Who Experience Motor Fluctuations
Peter A. LeWitt et al.
CLINICAL NEUROPHARMACOLOGY (2012)
Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity
Marija Usenovic et al.
JOURNAL OF NEUROSCIENCE (2012)
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Eun-Jin Bae et al.
JOURNAL OF NEUROSCIENCE (2012)
Perampanel, an AMPA antagonist, found to have no benefit in reducing off time in Parkinson's disease
Andrew Lees et al.
MOVEMENT DISORDERS (2012)
A Randomized, Double-Blind, Placebo-Controlled Trial of Safinamide as Add-on Therapy in Early Parkinson's Disease Patients
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2012)
Overcoming obstacles in Parkinson's disease
Todd B. Sherer et al.
MOVEMENT DISORDERS (2012)
Inflammation in Parkinson's disease: Cause or consequence?
Stanley H. Appel
MOVEMENT DISORDERS (2012)
Prion-like acceleration of a synucleinopathy in a transgenic mouse model
Anne-Laure Mougenot et al.
NEUROBIOLOGY OF AGING (2012)
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
Kelvin C. Luk et al.
SCIENCE (2012)
α-Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Mickael Decressac et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
Byoung Dae Lee et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Leucine-Rich Repeat Kinase 2 (LRRK2) Cellular Biology: A Review of Recent Advances in Identifying Physiological Substrates and Cellular Functions
Robert E. Drolet et al.
JOURNAL OF NEUROGENETICS (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
Bioactivity of AAV2-Neurturin Gene Therapy (CERE-120): Differences Between Parkinson's Disease and Nonhuman Primate Brains
Raymond T. Bartus et al.
MOVEMENT DISORDERS (2011)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease
Klaus Seppi et al.
MOVEMENT DISORDERS (2011)
AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials
Daniela Berg et al.
MOVEMENT DISORDERS (2011)
Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1-120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice
Tatyana A. Shelkovnikova et al.
NEURODEGENERATIVE DISEASES (2011)
Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death
Laura A. Volpicelli-Daley et al.
NEURON (2011)
Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease The STRIDE-PD Study
Fabrizio Stocchi et al.
ANNALS OF NEUROLOGY (2010)
Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains
Lydia Alvarez-Erviti et al.
ARCHIVES OF NEUROLOGY (2010)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Tolerability of Isradipine in Early Parkinson's disease: A Pilot Dose Escalation Study
Tanya Simuni et al.
MOVEMENT DISORDERS (2010)
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
Byoung Dae Lee et al.
NATURE MEDICINE (2010)
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management
Angelo Antonini et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2009)
Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease
Carol Addy et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases
Brian Spencer et al.
JOURNAL OF NEUROSCIENCE (2009)
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Etienne C. Hirsch et al.
LANCET NEUROLOGY (2009)
Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease
Yanping Li et al.
NATURE NEUROSCIENCE (2009)
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss
Luke S. Tain et al.
NATURE NEUROSCIENCE (2009)
Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions
Yaping Chu et al.
NEUROBIOLOGY OF DISEASE (2009)
The scientific and clinical basis for the treatment of Parkinson disease (2009)
C. Warren Olanow et al.
NEUROLOGY (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Is Parkinson's disease a prion disorder?
C. Warren Olanow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats
Feng Jin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy
Derek Narendra et al.
JOURNAL OF CELL BIOLOGY (2008)
Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration
Hui-Ming Gao et al.
JOURNAL OF NEUROSCIENCE (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
In vivo silencing of alpha-synuclein using naked siRNA
Jada Lewis et al.
MOLECULAR NEURODEGENERATION (2008)
Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations
Robert A. Hauser et al.
MOVEMENT DISORDERS (2008)
A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline as a Disease Modifying Therapy in Parkinson's Disease (The ADAGIO Study): Rationale, Design, and Baseline Characteristics
C. Warren Olanow et al.
MOVEMENT DISORDERS (2008)
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation
Jia-Yi Li et al.
NATURE MEDICINE (2008)
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
Jeffrey H. Kordower et al.
NATURE MEDICINE (2008)
The PINK1/Parkin pathway regulates mitochondrial morphology
Angela C. Poole et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Maryka Quik et al.
ANNALS OF NEUROLOGY (2007)
Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages
R. Andres Floto et al.
AUTOPHAGY (2007)
'Rejuvenation' protects neurons in mouse models of Parkinson's disease
C. Savio Chan et al.
NATURE (2007)
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease
Alessandro Stefani et al.
BRAIN (2007)
Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and α-synuclein
Sovan Sarkar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α
Marie Lagouge et al.
CELL (2006)
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused inactivation of Drosophila Pink1 is rescued by by Parkin
Yufeng Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Ira E. Clark et al.
NATURE (2006)
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Jeehye Park et al.
NATURE (2006)
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia
F Gardoni et al.
JOURNAL OF NEUROSCIENCE (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Effects of α-synuclein immunization in a mouse model of Parkinson's disease
E Masliah et al.
NEURON (2005)
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease - A clinical and pharmacokinetic study
F Stocchi et al.
ARCHIVES OF NEUROLOGY (2005)
The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease
J Jankovic et al.
PROGRESS IN NEUROBIOLOGY (2005)
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study)
CW Olanow et al.
CLINICAL NEUROPHARMACOLOGY (2004)
Neuroprotection in Parkinson disease - Mysteries, myths, and misconceptions
AHV Schapira et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
α-synuclein locus duplication as a cause of familial Parkinson's disease
MC Chartier-Harlin et al.
LANCET (2004)
α-synuclein locus triplication causes Parkinson's disease
AB Singleton et al.
SCIENCE (2003)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Aggregated and monomeric α-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function
H Snyder et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
JG Nutt et al.
NEUROLOGY (2003)
Effects of coenzyme Q10 in early Parkinson disease -: Evidence of slowing of the functional decline
CW Shults et al.
ARCHIVES OF NEUROLOGY (2002)
Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease
T Breidert et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures
KS McNaught et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
A Abeliovich et al.
NEURON (2000)
Share Paper
